S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014|
|Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast|
|Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference|
|Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference|
|Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference|
|Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch|
|Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)|
|Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston|
|Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults|
|TRACON Pharmaceuticals Completes $27 Million Financing and Expands Management Team and Board of Directors (2014/9/22)|
Click above to view more mutual fund data and stats for orex - Orexigen Therapeutics Inc.